NTRA · Natera Inc
Price
Snapshot
50 fields · last close| Market Cap | $47.23B |
| P/E | — |
| Float | 138.8M |
| Beta | 1.61 |
| Volatility | 40.2% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Large cap |
| Macro sensitivity | High |
| Clavix score | 64 |
| Price | 325.62 |
| Change | −0.63% |
| Prev Close | 327.67 |
| Open | 325.65 |
| Day Low | 320.01 |
| Day High | 332.00 |
| Avg Vol | 1 |
| Avg $ Vol | $397.6M |
| 52W High | 343.18 |
| 52W Low | 157.43 |
| 52W Pos | 90.5% |
| From High | −5.12% |
| From Low | +106.84% |
| Max DD 1Y | −28.20% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +0.79% |
| SMA 50 | +11.93% |
| SMA 200 | +38.54% |
| RSI (14) | 61.8 |
| Vol 30D | 64.8% |
| Vol 90D | 56.9% |
| 1Y Range | 157–343 |
| Daily bars | 506 |
| Perf Week | −3.26% |
| Perf Month | +19.32% |
| Perf Quarter | +47.53% |
| Perf Half Y | +66.21% |
| Perf Year | +95.59% |
| Perf YTD | +42.29% |
| Prev Day | −0.63% |
| Clavix | B- |
| Debt / Eq | 0.05 |
| Curr Ratio | 3.39 |
| Int Cover | -39.2× |
| FCF Margin | 2.8% |
| Rev Growth | +37.7% |
| Profit | Unprofitable |
| Leverage | Low |
| Sector rank | 24 / 35 |
Clavix risk grade
regraded every trading dayNTRA grades B-, 64 of 100. Steadiest on Sector Resilience (66), most exposed on Price Stability (43, fragile). 1 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 24 of 35 in Biotechnology by Clavix score.
How rough the ride is
| NTRA | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 1.61 | 0.50 |
| Volatilityannualized | 40.2% | 13.2% |
| Max drawdown, past yearworst peak-to-trough fall | −28.2% | — |
| Typical daily movemedian absolute daily change | 1.61% | — |
| Days beyond ±3%of the last 252 sessions | 6425% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| NTRA | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 1.61 | 0.50 |
| Macro sensitivityrate, dollar and credit exposure bucket | High | Low56% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| NTRA | |
|---|---|
| 1 week | −3.3% |
| 1 month | +19.3% |
| Year to date | +42.3% |
| 1 year | +95.6% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| NTRA | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30since 5 Aug |
| Average score0 most bearish, 100 most bullish | 72 |
| Bullish · bearisharticles above 60 · below 40 | 28 · 0 |
| Directionarticles whose tone is improving vs worsening | 28 ↑ 0 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| NTRA | |
|---|---|
| Revenue growthyear over year | +37.7% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Against Biotechnology
36 companies| Metric | NTRA | Sector spread | Median |
|---|---|---|---|
| Beta | 1.61 | 0.50 | |
| Volatility | 40.2% | 13.2% | |
| Debt / equity | 0.05 | 0.24 | |
| Current ratio | 3.39 | 3.73 | |
| FCF margin | 2.8% | 29.1% | |
| Interest coverage | -39.2× | -0.2× |
Recent news
most recent scored articles · the chip is the article’s score · click to openNatera is partnering with Angiex to use its Signatera blood test in a Phase 1 trial of Angiex's experimental cancer drug AGX101, aiming to track treatment response by measuring tumor DNA fragments in patients' blood.
Natera (NTRA) is partnering with biotech company Angiex to use its Signatera blood test in a Phase 1 trial of Angiex's cancer drug AGX101. The goal is to track circulating tumor DNA, tiny fragments of cancer genetic material in the blood, so researchers can better measure how patients respond to treatment.
Natera announced a national partnership with Susan G. Komen, the breast cancer nonprofit, to raise awareness and education, including around MRD (minimal residual disease, meaning small amounts of cancer that may remain after treatment). The company's Signatera test, which detects MRD, was highlighted as backed by over 185 peer-reviewed publications.
Natera announced a national partnership with Susan G. Komen, the leading breast cancer nonprofit, to raise awareness and education around breast cancer, including efforts to grow understanding of MRD (minimal residual disease) testing. Natera's Signatera MRD test is backed by more than 185 peer-reviewed studies across multiple cancer types.
Canada Pension Plan Investment Board bought a new position in Natera during the second quarter, purchasing 124,300 shares valued at approximately $33.74 million, according to its 13F filing.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| RVMD | Revolution Medicines Inc | B- | $45.20B | — | 1.44 | Compare |
| MRNA | Moderna Inc | F | $59.43B | — | 1.22 | Compare |
| ALNY | Alnylam Pharmaceuticals Inc | C | $35.39B | 44.28 | 0.34 | Compare |
| BIIB | Biogen Inc | B+ | $33.17B | 39.72 | 0.12 | Compare |
| INSM | Insmed Inc | C- | $27.66B | — | 0.82 | Compare |
| INCY | Incyte Corp | B+ | $25.95B | 16.10 | 0.78 | Compare |
| REGN | Regeneron Pharmaceuticals Inc | B+ | $86.84B | 20.26 | 0.12 | Compare |
| UTHR | United Therapeutics Corp | A- | $21.89B | 16.03 | 0.51 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.